326 related articles for article (PubMed ID: 31877123)
1. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy.
Verma M; Shimizu-Motohashi Y; Asakura Y; Ennen JP; Bosco J; Zhou Z; Fong GH; Josiah S; Keefe D; Asakura A
PLoS Genet; 2019 Dec; 15(12):e1008468. PubMed ID: 31877123
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
3. Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice.
Verma M; Asakura Y; Hirai H; Watanabe S; Tastad C; Fong GH; Ema M; Call JA; Lowe DA; Asakura A
Hum Mol Genet; 2010 Nov; 19(21):4145-59. PubMed ID: 20705734
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
6. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
7. Supplementation with a selective amino acid formula ameliorates muscular dystrophy in mdx mice.
Banfi S; D'Antona G; Ruocco C; Meregalli M; Belicchi M; Bella P; Erratico S; Donato E; Rossi F; Bifari F; Lonati C; Campaner S; Nisoli E; Torrente Y
Sci Rep; 2018 Oct; 8(1):14659. PubMed ID: 30279586
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
9. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
Palladino M; Gatto I; Neri V; Straino S; Smith RC; Silver M; Gaetani E; Marcantoni M; Giarretta I; Stigliano E; Capogrossi M; Hlatky L; Landolfi R; Pola R
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2867-76. PubMed ID: 24072696
[TBL] [Abstract][Full Text] [Related]
11. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
12. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.
Xin C; Chu X; Wei W; Kuang B; Wang Y; Tang Y; Chen J; You H; Li C; Wang B
Hum Mol Genet; 2021 Jun; 30(14):1349-1359. PubMed ID: 33987645
[TBL] [Abstract][Full Text] [Related]
13. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
[TBL] [Abstract][Full Text] [Related]
14. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
[TBL] [Abstract][Full Text] [Related]
15. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.
Oliveira-Santos A; Dagda M; Burkin DJ
Hum Mol Genet; 2022 Jul; 31(14):2358-2369. PubMed ID: 35157045
[TBL] [Abstract][Full Text] [Related]
17. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.
Miyazaki D; Nakamura A; Fukushima K; Yoshida K; Takeda S; Ikeda S
Hum Mol Genet; 2011 May; 20(9):1787-99. PubMed ID: 21320869
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
